BioSpace News Archive

Intelligent Bio Solutions Inc. announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock, Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock and associated Series H-1 warrants and Series H-2 warrants.

Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the “Sanyou Intelligent Innovative Biologics R&D Service Platform,” representing a transformative advancement in biopharmaceutical research and development.

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.

Arctic Therapeutics today announced approval by the European Medicines Agency (EMA) for initiation of the first clinical trial evaluating AT-001 (Nacuity’s NPI-001) for the treatment of Hereditary Cystatin C Amyloid Angiopathy (HCCAA) in Iceland.

RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.

Truveris elevates Garrett Fienberg to Chief Operating Officer, Gregg DiPietro to Chief Commercial Officer, and Louise Shea to Chief Pharmacy Officer.

Glucotrack, Inc. announced today that Vincent Wong has joined the Company as Vice President of Quality.

The Lung Cancer Research Foundation (LCRF) has announced three research grant awards funded by Daiichi Sankyo and AstraZeneca, totaling $810,000.

Cognitive impairment is prevalent in patients living with heart failure and was shown to negatively impact functional abilities, life expectancy, medication management and patient self-care, a statement released by the Heart Failure Society of America (HFSA) revealed.

Saghmos Therapeutics, Inc. announced that it has received a Notice of Allowance from the Japanese Patent Office for a patent for its Phase 3-ready product, ST-62516.